Adding Xtandi (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic castration-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results announced by Pfizer and Astellas Pharma, the drug developers, also show that the safety profile of Xtandi in this population is consistent with previous clinical trials. “Many prostate cancer patients who initiate androgen deprivation therapy will experience disease progression illustrated by a rising PSA level, and currently, there are no FDA-approved treatment options for patients with non-metastatic CRPC until they develop confirmed radiographic metastatic disease,” Dr. Neal Shore, MD, direc